» Articles » PMID: 28135843

A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 2017 Feb 1
PMID 28135843
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The authors examined whether a contingency management intervention using the ethyl glucuronide (EtG) alcohol biomarker resulted in increased alcohol abstinence in outpatients with co-occurring serious mental illnesses. Secondary objectives were to determine whether contingency management was associated with changes in heavy drinking, treatment attendance, drug use, cigarette smoking, psychiatric symptoms, and HIV-risk behavior.

Method: Seventy-nine (37% female, 44% nonwhite) outpatients with serious mental illness and alcohol dependence receiving treatment as usual completed a 4-week observation period and were randomly assigned to 12 weeks of contingency management for EtG-negative urine samples and addiction treatment attendance, or reinforcement only for study participation. Contingency management included the variable magnitude of reinforcement "prize draw" procedure contingent on EtG-negative samples (<150 ng/mL) three times a week and weekly gift cards for outpatient treatment attendance. Urine EtG, drug test, and self-report outcomes were assessed during the 12-week intervention and 3-month follow-up periods.

Results: Contingency management participants were 3.1 times (95% CI=2.2-4.5) more likely to submit an EtG-negative urine test during the 12-week intervention period, attaining nearly 1.5 weeks of additional alcohol abstinence compared with controls. Contingency management participants had significantly lower mean EtG levels, reported less drinking and fewer heavy drinking episodes, and were more likely to submit stimulant-negative urine and smoking-negative breath samples, compared with controls. Differences in self-reported alcohol use were maintained at the 3-month follow-up.

Conclusions: This is the first randomized trial utilizing an accurate and validated biomarker (EtG) to demonstrate the efficacy of contingency management for alcohol dependence in outpatients with serious mental illness.

Citing Articles

Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trial.

Muyindike W, Fatch R, Lodi S, Emenyonu N, Kekibiina A, Adong J EClinicalMedicine. 2025; 80:103045.

PMID: 39867970 PMC: 11764067. DOI: 10.1016/j.eclinm.2024.103045.


Participant experiences with a text message and contingency management intervention for alcohol use during pregnancy and lactation in Cape Town, South Africa.

Erasmus-Claassen L, Mpisane N, Williams P, Browne F, Myers B, Wechsberg W Res Sq. 2024; .

PMID: 39315252 PMC: 11419270. DOI: 10.21203/rs.3.rs-4900516/v1.


Use of Transdermal Alcohol Sensors in Conjunction With Contingency Management to Reduce Alcohol Consumption in People With Alcohol Dependence Attending Alcohol Treatment Services: Protocol for a Pilot Feasibility Randomized Controlled Trial.

Brobbin E, Deluca P, Parkin S, Drummond C JMIR Res Protoc. 2024; 13:e57653.

PMID: 39083798 PMC: 11325106. DOI: 10.2196/57653.


Contingency Management for Drug Use Disorders: Meta-Analysis and Application of Tolin's Criteria.

Pfund R, Ginley M, Boness C, Rash C, Zajac K, Witkiewitz K Clin Psychol (New York). 2024; 31(2):136-150.

PMID: 38863566 PMC: 11164545. DOI: 10.1037/cps0000121.


Participant perspectives on incentives for TB preventative therapy adherence and reduced alcohol use: A qualitative study.

Appa A, Miller A, Fatch R, Kekibiina A, Beesiga B, Adong J PLOS Glob Public Health. 2024; 4(4):e0002472.

PMID: 38656992 PMC: 11042709. DOI: 10.1371/journal.pgph.0002472.


References
1.
Buckley P . Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. J Clin Psychiatry. 2006; 67 Suppl 7:5-9. View

2.
Bellack A, Bennett M, Gearon J, Brown C, Yang Y . A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006; 63(4):426-32. DOI: 10.1001/archpsyc.63.4.426. View

3.
Brunette M, Asher D, Whitley R, Lutz W, Wieder B, Jones A . Implementation of integrated dual disorders treatment: a qualitative analysis of facilitators and barriers. Psychiatr Serv. 2008; 59(9):989-95. DOI: 10.1176/ps.2008.59.9.989. View

4.
Holtyn A, Koffarnus M, DeFulio A, Sigurdsson S, Strain E, Schwartz R . The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. Prev Med. 2014; 68:62-70. PMC: 4155024. DOI: 10.1016/j.ypmed.2014.02.021. View

5.
McDonell M, Skalisky J, Leickly E, McPherson S, Battalio S, Nepom J . Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients. Drug Alcohol Depend. 2015; 157:184-7. PMC: 4663163. DOI: 10.1016/j.drugalcdep.2015.10.004. View